13 results about "Dihydrolipoic acid" patented technology

The invention relates to a culture medium for high-density serum-free suspension culture of BHK-21 cells and application of the culture medium. The culture medium contains inorganic salt, amino acid, vitamins, energy substances, a buffer substance, an antioxidant, sterol, polyamine, an additive and an indicator, and the antioxidant comprises dihydrolipoic acid and S-acetyl-L-glutathione. According to the invention, the culture medium for serum-free suspension culture of the BHK-21 cells, which is clear in components and remarkable in culture effect, can be provided. The added dihydrolipoic acid and S-acetyl-L-glutathione are combined as antioxidants of the culture medium, so that the survival rate of BHK-21 cells cultured in the culture medium is improved while the oxidation resistance of the serum-free suspension culture medium is improved.

The present application relates to a kind of hyperbranched polymer, nano preparation and its preparation method and application, belong to functional medical material and nanotechnology field.The hyperbranched polymer of the present application can be broken in ROS environment Release dihydrolipoic acid, play the role of antioxidant, be reduced to lipoic acid in vivo, and then play its role as coenzyme, participate in mitochondrial tricarboxylic acid cycle, restore mitochondrial function, thereby play the role of antioxidant and play the role of treating ischemic stroke.The nano preparation provided by the present application can be quickly distributed to brain in a short time, temporarily increase the paracellular permeability of BBB by inhibiting the expression of multi-drug resistance protein P-gp and ATP-dependent drug efflux protein on BBB, and the process of opening BBB by borneol is physiological and reversible, without destroying the structural integrity of blood-brain barrier.

A method of preparing ( R)-dihydrolipoic acid (RDLA) is disclosed. In various embodiments described herein, the method of producing RDLA minimizes yield loss due to the oxidation of RDLA to lipoic acid. The method of producing RDLA minimizes the evolution of hydrogen gas during the reduction of lipoic acid to RDLA. The method includes selectively reducing the disulfide bond in the cyclic moiety of alpha-lipoic acid (shown below) without reducing the carboxylic acid moiety.

The present invention related to a compound for use in prevention or treatment of a neurodegenerative disease associated with the formation of stress granules. The compound is selected from lipoic acid, lipoamide, dihydrolipoic acid, and dihydrolipoamide. The invention further relates to a method of identifying a compound that modulates a characteristic associated with one or more condensates comprising a condensate-associated molecule, comprising: (a) contacting the compound with a cellular composition comprising one or more condensates or a cellular composition capable of forming one or more condensates, and (b) determining the characteristic associated with the one or more condensates. A modulation in the characteristic, as compared to a reference, indicates that the compound modulates the characteristic associated with the one or more condensates.

The invention provides a method for synthesizing DL-lipoic acid, which comprises the following steps of: adding sodium persulfate and a catalyst into dihydrolipoic acid serving as a raw material in a neutral or weakly alkaline environment, heating to react, and purifying to obtain the DL-lipoic acid, the catalyst is a metal compound loaded on a microsphere carrier; the metal compound is selected from at least one of metal oxide and metal salt; the molecular formula of the microsphere carrier is MgCl2. N (ROH), n is 3-6, and R is C2-C6 saturated alkyl; the metal oxide adopts iron oxide or chromium oxide; the metal salt adopts ferric trichloride or chromium trichloride. According to the method, the metal compound loaded on the microsphere carrier is used as the catalyst, and in a neutral or weakly alkaline environment, dihydrolipoic acid is used as a raw material, and sodium persulfate is used as the catalyst, so that the yield and purity of the target product DL-lipoic acid are effectively improved, and the reaction time is shortened.

The invention discloses a silver nanocluster with red emission and detection and antibacterial properties thereof, the silver nanocluster is prepared by adopting dihydrolipoic acid as a ligand and sodium borohydride as a reducing agent through an optimized synthesis process, the quantum yield is as high as 14.8%, the fluorescence lifetime is 7.91 microseconds, and the silver nanocluster has excellent fluorescence characteristics and stability. High-selectivity detection of the heavy metal ion Ni < 2 + > can be realized based on a fluorescence resonance energy transfer mechanism, and the detection limit is as low as 68 nM. Meanwhile, four types of tetracycline antibiotics (TCs) of oxytetracycline (OTC), tetracycline (TC), doxycycline (DOX) and aureomycin (CTC) are recognized through specific ratio fluorescence response. The compound has an efficient inhibition effect on common pathogenic bacteria such as gram-positive bacteria and gram-negative bacteria, and the bacteriostasis rate reaches 80% or above. The hydrogel dressing prepared by compounding AgNCs and a natural polymer material sodium alginate can effectively inhibit wound infection and promote tissue regeneration and wound healing.

The invention relates to a method for synthesizing lipoic acid, which comprises the following steps of: reacting adipic acid monoester serving as an initial raw material with an acylating chlorination reagent to obtain adipic acid ester monoacyl chloride; the preparation method comprises the following steps: reacting acetaldehyde with an amine compound to obtain N-vinylpyrrolidine, carrying out condensation reaction on adipate monoacyl chloride and N-vinylpyrrolidine to obtain 6, 8-dioxocaprylic acid ethyl ester, reducing to obtain 6, 8-dihydroxy caprylic acid ethyl ester, reacting 6, 8-dihydroxy caprylic acid ethyl ester with thiourea in the presence of hydroiodic acid, hydrolyzing and acidifying to obtain dihydrolipoic acid, and oxidizing to obtain lipoic acid. The process has the advantages of easily available raw materials, few synthesis steps, high yield and good product quality, and is suitable for industrial production.

The present invention relates to a compound for use in the prevention or treatment of neurodegenerative diseases associated with the formation of stress particles. The compound is selected from the group consisting of lipoic acid, lipoic acid amide, dihydrolipoic acid and dihydrolipoic acid amide. The invention further relates to a method of identifying a compound that modulates a property associated with one or more agglomerates comprising an agglomerate-related molecule, comprising: (a) contacting the compound with a cellular composition comprising one or more agglomerates or a cellular composition capable of forming one or more agglomerates, and (b) determining a property associated with the one or more agglomerates. The modulation of the property as compared to a reference indicates that the compound modulates a property associated with the one or more agglomerates.

Long term storage stable fulvestrant-containing compositions are disclosed. The compositions can include fulvestrant; a solvent selected from dimethyl sulfoxide (DMSO), glycofurol, N-methyl pyrrolidone, and mixtures thereof; an oil mixture selected from a mixture of caprylic and capric triglycerides, a mixture of caprylic, capric and linoleic triglycerides, a mixture of caprylic, capric and succinic triglycerides, and a mixture of propylene glycol dicaprylate and propylene glycol dicaprate; and a sustained release member selected from benzyl benzoate, dihydrolipoic acid, benzyl alcohol and lipoic acid. The fulvestrant-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 24 months of storage at a temperature of from about 5° C. to about 25° C.

The present invention related to a compound for use in prevention or treatment of a neurodegenerative disease associated with the formation of stress granules. The compound is selected from lipoic acid, lipoamide, dihydrolipoic acid, and dihydrolipoamide. The invention further relates to a method of identifying a compound that modulates a characteristic associated with one or more condensates comprising a condensate-associated molecule, comprising: (a) contacting the compound with a cellular composition comprising one or more condensates or a cellular composition capable of forming one or more condensates, and (b) determining the characteristic associated with the one or more condensates. A modulation in the characteristic, as compared to a reference, indicates that the compound modulates the characteristic associated with the one or more condensates.

This invention discloses a method for preparing dihydrolipoic acid, relating to the field of pharmaceutical synthesis technology. The invention comprises the following steps: a) using a low-carbon alcohol as a reaction solvent, adding 6,8-dichlorooctanoic acid methyl ester, sodium sulfide nonahydrate, and sulfur, heating to reflux, and cooling and filtering after the reaction is completed; b) adding water and a metal reducing agent to the filtrate, heating to reflux under nitrogen protection, and then cooling to room temperature; c) adjusting the solution pH to 1-2 with dilute hydrochloric acid or the like, and recovering the alcoholic reaction solvent under reduced pressure; d) extracting the product with an organic solvent, and finally distilling under reduced pressure to obtain the product. This invention uses inexpensive 6,8-dichlorooctanoic acid methyl ester as the base raw material and readily available and inexpensive metal reducing agents, which can effectively reduce costs, have low requirements for reaction conditions, and reduce the difficulty of preparation.

The application belongs to the technical field of biological medicine, and particularly relates to an adrenaline injection and a preparation method thereof. The application provides an adrenaline injection, 1 mg of adrenaline, 9 mg of sodium chloride, 0.02%-0.5% of dihydrolipoic acid, 0.05%-0.5% of disodium edetate, and appropriate hydrochloric acid are contained in each 1 mL of the injection, and the rest is water for injection. The dihydrolipoic acid and the disodium edetate are innovatively added in the prescription as antioxidants, and the antioxidants synergistically play a stabilizing role. The prescription process of the application has good applicability and high stability, the injection can be subjected to terminal sterilization, and the safety and effectiveness of the product in the clinical use can be fully ensured.

This invention relates to a culture medium for high-density serum-free suspension culture of BHK-21 cells and its application. The culture medium contains inorganic salts, amino acids, vitamins, energy substances, buffers, antioxidants, sterols, polyamines, additives, and indicators. The antioxidants include dihydrolipoic acid (DLA) and S-acetyl-L-glutathione. This invention provides a culture medium with clearly defined components and significant culture effects for serum-free suspension culture of BHK-21 cells. The added DLA and S-acetyl-L-glutathione, as a combination of antioxidants in the culture medium, enhance the antioxidant properties of the serum-free suspension medium while also improving the cell viability of BHK-21 cells cultured in the medium.